Kancera develops drug candidates with a proven ability to work effectively and directly against cancer. The business model is based on:
The market is witnessing a shift in terms of the development stage of acquisition of drug candidates. The traditional licensing deals at Proof of Concept (Clinical phase II) are being replaced by agreements that are secured late in clinical phase III or during the preclinical phase, where Kancera has a competitive edge.
A reason for this change is that experience has shown that many clinical phase I/II projects on the market do not fulfill required quality standards. In other words, the projects run an increased risk of failing or being dramatically delayed unless there is significant additional investment in the project.
For this reason, the established pharmaceutical companies are now ever more frequently establishing alliances through option agreements in the preclinical phase with innovators such as Kancera to develop drug candidates meeting the quality criteria required to deliver a medically and commercially successful pharmaceutical.